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independently of absorbed doses distribution, together with 
abnormal mitosis. The latter results indicate that bystander 
effects could also be involved. However, at this stage, we 
may assume that they do not fully counterbalance the lack of 
efficacy due to heterogeneous distribution of anti-CEA 212Pb-
mAbs, possibly because lesions are not as complex as those 
produced by high LET radiation.  
Conclusions: Our results showed in vitro and in vivo that, 
besides the strong direct effect of 212Pb-labeled mAbs in 
killing tumour cells, bystander effects have also to be 
considered.  
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Radiotherapy is an important treatment modality for millions 
of patients with cancer worldwide. Current treatment 
decisions do not take into account individual patients’ or 
cohorts of patients’ sensitivities to this treatment modality. 
As such, patients treated with radiation therapy experience a 
large variation in normal tissue toxicity that results in dose-
limiting acute and irreversible progressive side effects. 
Important examples of these adverse effects include 
mucositis, pneumonitis, and cognitive damage, respectively 
representing acute, intermediate, and late effects. 
Stratification of patients based on radiation sensitivities will 
allow delivery of suitable alternative treatments to high-risk 
patients and dose escalation to tumors in less sensitive 
patients. Current focus on radiation 
biomarkers/biodosimeters appears to be primarily to assess 
radiation doses after catastrophic accidental radiation 
exposure. Recent advances have brought together several 
cross-disciplinary areas such as biological assays, analytical 
platforms, and algorithms to rapidly assess dose to 
individuals. These technologies are at different maturation 
levels. This immense progress is also an opportunity to use 
them to predict heterogeneity of radiation sensitivities 
among cancer patients to improve radiation therapy outcome 
and their quality of life. This talk will emphasize the need 
for discovery, development, and validation of predictive 
biomarkers, provide some examples of biomarkers, and 
discuss the translational challenges involved in leveraging 
advances in radiation-specific biomarker research to 
radiotherapy, which for the foreseeable future likely to 
remain a cornerstone of cancer treatment.  
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Purpose: Range verification in proton therapy is highly 
desirable to fully exploit the advantageous properties of 
proton beams for tumor therapy. In this context, prompt 
gamma imaging (PGI) is of growing interest and different 
technical concepts for realization are currently under 
investigation. The feasibility of range shift detection with a 
slit camera has previously been shown for different targets 
irradiated with protons in pencil beam scanning mode [1-3]. 
In preparation of the clinical application of the slit camera 
within a patient study, we report on the first application of 
the slit camera to passively shaped proton beams.  
Materials / Methods: Targets with increasing complexity have 
been irradiated with passively shaped proton beams (double 
scattering mode). For artificial range shift induction, the 
energy of the protons was varied. Prompt gamma emission 
was monitored by means of a knife-edge shaped slit camera.  
Prompt gamma rays emitted during the irradiation are 
projected through a slit aperture onto a segmented detector. 
Thus, a one-dimensional depth distribution of detected 
prompt gamma rays is obtained.  
In double scattering mode, a high neutron induced 
background hampers direct range shift evaluation from these 
detected gamma distributions. In order to quantify this 
background, measurements have been repeated with a closed 
slit aperture of the camera. This facilitates a subtraction of 
the background from the measurements with open slit. 
Time resolved analysis of the measurements allows for a 
mapping of single prompt gamma profiles to different steps 
of the range modulator wheel, and, thus, to different iso-
energy layers. 
Results: Global range shifts of several millimeters in 
homogeneous as well as inhomogeneous targets were 
detected with the slit camera measurement during proton 
irradiation with passive field formation. Figure 1 shows the 
experimental setup with a head target (left) and detected 
prompt gamma profiles for different proton energies, i.e. 
different requested proton ranges (right). Separation of 
different prompt gamma profiles related to single steps of 
the range modulator wheel was possible. 
 
 
 
Figure 1: Left: Experimental setup of a prompt gamma slit 
camera measurement during irradiation of a head phantom 
with a passively shaped proton beam. Right: Measured 
prompt gamma depth profiles, normalized to the applied 
monitor units (MU) for different requested proton ranges, i.e. 
different proton energies. 
 
Conclusions: In preparation of the application of the slit 
camera to patient treatment, we investigated the 
detectability of range shifts in double scattering proton 
irradiation. Global range shifts of a few millimeters were 
detected from measurements with the slit camera. Time 
resolved analysis allows for separation of prompt gamma 
profiles correlated to protons of different iso-energy layers. 
This might provide additional information on potential 
sources of range deviations. 
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MEDICIS-PROMED aims to develop a network of academic, 
medical and industrial partners providing an extensive 
doctoral program to 15 young scientists in the field of new 
personalized treatments using radioisotope beams, notably 
for treatment of ovarian cancer. 
This field is expected to expand rapidly and provide new 
types of treatments combining imaging and personalized 
treatment with the same radiopharmaceutical and different 
types of isotopes, emitting positron or gamma light for 
imaging on one side, and Auger electron, beta and alpha 
radiation for treatment on the other side, known as 
theranostics pairs [1]. In addition, positron emitting isotopes 
such as 11Carbon can personalize hadron therapy treatments 
by imaging the dose distribution of the implanted ions [2,3]. 
In this scheme, CERN, the European Organization for Nuclear 
Research is the coordinating partner, and collaborates with 
local hospitals which are able to exploit short-lived isotopes 
produced in the newly constructed CERN-MEDICIS facility. It 
also fits within an extended network of high-technology 
companies and leading academic research institutes, which 
will design new components for the development or tests of 
innovative radiopharmaceuticals and imaging agents for 
personalized treatment. It brings world-class researchers 
together in the field of lasers and isotope mass separation, 
accelerators, material science, oncology, entrepreneurial 
radiopharmaceutical production, and imaging, to propose 
new solutions to the second deadliest cancer for women. 
The program will develop along three R&D work packages 
integrating multidisciplinary intersectorial training teams: 
• Development of new radioisotopes and techniques using 
isotope mass separation for medicine and based on CERN-
MEDICIS. 
• Development and test of 11Carbon PET-aided hadron 
therapy. 
• Synthesis & tests of radiopharmaceuticals to diagnose and 
treat ovarian cancer. 
Because of the unique capability of CERN-MEDICIS to produce 
medical batches of innovative isotopes, such as 149Terbium 
[4] and thanks and to the new generation of young scientists 
that will be trained in the relevant fields the MEDICIS-
PROMED innovative training network will significantly 
advance the use of radioisotopes for personalized medicine in 
Europe and go beyond the present common practices. 
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Purpose: Experimental data for the impact of fractionated 
proton beam exposures is limited. Using acute exposures, the 
current clinical adoption of a generic, constant cell killing 
RBE has been shown to underestimate the effect of the sharp 
increase in Linear Energy Transfer (LET) in the distal regions 
of the spread-out Bragg peak (SOBP).  Here we aim to 
investigate the clinical implications of a variable Relative 
Biological Effectiveness (RBE) on proton dose fractionation.  
Methods and Materials: Human fibroblasts (AG01522) were 
irradiated with 219.65 MeV protons at four depth positions 
along a clinical SOBP. These were delivered as fractionated 
regimes with an inter-fraction period of 24 hours at the 
Prague Proton Therapy Centre.  Cell killing RBE variations 
were measured using standard clonogenic assays and were 
further validated using Monte Carlo simulations and 
parameterized using a Linear-Quadratic formalism. 
Results: Consistent with previous studies of a single fraction 
response for both survival and DNA damage (DSB foci) (1,2), 
significant variations in the cell killing RBE for fractionated 
exposures along the proton dose profile were observed.  The 
RBE increased sharply towards the distal position, 
corresponding to a reduction in the cell sparing effectiveness 
of fractionated proton exposures at lower energies and 
higher LET.  The effect is more pronounced at smaller doses 
per fraction. Experimental survival fractions were adequately 
predicted using a Linear Quadratic formalism assuming full 
repair between fractions.  The data were also used to 
validate a parameterized variable RBE model based on linear 
alpha parameter response with LET that showed considerable 
deviations from clinically predicted isoeffective fractionation 
regimes. 
Conclusions: The biologically effective dose calculated using 
the clinically adopted generic RBE of 1.1 significantly 
underestimates the biological effective dose from variable 
RBE for single and fractionated regimes with low doses per 
fraction.  Coupled with an increase in effective range in 
fractionated exposures, the study indicates the needs for the 
optimization of proton therapy particularly in the move 
towards hypofractionation. 
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